{"id":2797,"date":"2018-07-19T15:38:57","date_gmt":"2018-07-19T10:08:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2797"},"modified":"2021-07-24T12:57:00","modified_gmt":"2021-07-24T07:27:00","slug":"business-cocktaildrug","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f12f4575ae7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f12f4575ae7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug\/#Sanofi_bags_rights_to_Revolutions_SHP2_cancer_drug\" >Sanofi bags rights to Revolution\u2019s SHP2 cancer drug<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug\/#Pfizer_Lilly_tout_positive_tanezumab_data_but_safety_questions_remain\" >Pfizer, Lilly tout positive tanezumab data, but safety questions remain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug\/#Ascentage_third_round_garners_150M_for_apoptosis_cancer_drugs\" >Ascentage third round garners $150M for apoptosis cancer drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug\/#Celgene_Takeda_invest_in_intratumoral_microdosing_firm_Presage\" >Celgene, Takeda invest in intratumoral microdosing firm Presage<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Sanofi_bags_rights_to_Revolutions_SHP2_cancer_drug\"><\/span>Sanofi bags rights to Revolution\u2019s SHP2 cancer drug<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drugs against SHP2. The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year. Sanofi has also committed to covering the R&amp;D costs of the joint SHP2 program and paying out up to $500 million in development and commercial milestones. RMC-4630, is due to enter a first in human trial. The drug could target a range of indications, but Sanofi has singled out one disease in its discussions of the collaboration.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Pfizer_Lilly_tout_positive_tanezumab_data_but_safety_questions_remain\"><\/span>Pfizer, Lilly tout positive tanezumab data, but safety questions remain<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Pfizer and Eli Lilly on Wednesday\u00a0<a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_and_lilly_announce_positive_top_line_results_from_phase_3_trial_of_tanezumab_for_the_treatment_of_osteoarthritis_oa_pain\">announced positive topline results<\/a>\u00a0for their osteoarthritis pain drug tanezumab in a Phase 3 trial of 698 patients.The study showed a statistically significant improvement in pain, physical function and patient overall assessment of osteoarthritis. No further details of the data were disclosed at this time.Safety data showed that 1% of patients discontinued due to adverse events, the companies said. Rapidly progressing osteoarthritis occurred in less than 1.5% of tanezumab-treated patients \u2014 but not at all in the placebo patients \u2014 while no events of osteonecrosis were seen.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Ascentage_third_round_garners_150M_for_apoptosis_cancer_drugs\"><\/span>Ascentage third round garners $150M for apoptosis cancer drugs<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Chinese biotech Ascentage has raised another $150 million for its pipeline of drugs designed to induce programmed cell death in cancer, which should keep it going for three years, according to its co-founder and CEO. Its portfolio is currently headed by BCL-2\/BCL-xL dual inhibitor\u00a0<strong>APG-1252<\/strong>\u00a0for small cell lung cancer (SCLC) and other solid tumors and IAP inhibitor\u00a0<strong>APG-1387<\/strong>, for which preliminary safety data were presented at this year\u2019s ASCO meeting. Slightly further back in development are a selective BCL-2 inhibitor called APG-2575 for B-cell cancers and MDM2-p53-targeting drug APG-115 for <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\">acute myeloid leukemia<\/a> and chronic lymphocytic leukemia, as well as three \u2018next-generation\u2019 kinase inhibitors in development for the Chinese market only. The\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/ascentage-pharma-raises-150-million-in-series-c-financing-300681870.html\"><strong>latest round<\/strong><\/a>\u00a0takes the total raised by Ascentage to date to $240 million.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Celgene_Takeda_invest_in_intratumoral_microdosing_firm_Presage\"><\/span>Celgene, Takeda invest in intratumoral microdosing firm Presage<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Celgene and Takeda have invested in Presage Biosciences. The company also announced that Dr\u00a0Richard Klinghoffer, is new chief executive.\u00a0Dr Klinghoffer will take over CEO responsibilities from\u00a0Nathan Caffo, who is now senior corporate advisor. Presage wants to provide a bridge between preclinical and phase 1 to enable drug developers to find out how their drugs perform in humans without spending as much time and money. Companies have explored the use of such a bridge, known as phase 0 for years, but Presage has a different take.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi bags rights to Revolution\u2019s SHP2 cancer drug Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drugs against SHP2. The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year. Sanofi has also committed to covering the R&amp;D costs of the joint SHP2 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[155,228,460,533,554],"industry":[17225],"therapeutic_areas":[17241,17228],"class_list":["post-2797","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-celgene","tag-eli-lilly","tag-pfizer","tag-sanofi","tag-takeda","industry-pharmaceutical","therapeutic_areas-musculoskeletal","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Latest pharma happenings for Celgene, Takeda, Ascentage, Pfizer and Lilly<\/title>\n<meta name=\"description\" content=\"Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drug against SHP2. The partners plan to move small.........\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Latest pharma happenings for Celgene, Takeda, Ascentage, Pfizer and Lilly\" \/>\n<meta property=\"og:description\" content=\"Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drug against SHP2. The partners plan to move small.........\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-19T10:08:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1100\" \/>\n\t<meta property=\"og:image:height\" content=\"618\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Latest pharma happenings for Celgene, Takeda, Ascentage, Pfizer and Lilly","description":"Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drug against SHP2. The partners plan to move small.........","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug","og_locale":"en_US","og_type":"article","og_title":"Latest pharma happenings for Celgene, Takeda, Ascentage, Pfizer and Lilly","og_description":"Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drug against SHP2. The partners plan to move small.........","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-07-19T10:08:57+00:00","article_modified_time":"2021-07-24T07:27:00+00:00","og_image":[{"width":1100,"height":618,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug","name":"Latest pharma happenings for Celgene, Takeda, Ascentage, Pfizer and Lilly","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","datePublished":"2018-07-19T10:08:57+00:00","dateModified":"2021-07-24T07:27:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drug against SHP2. The partners plan to move small.........","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktaildrug#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail.jpg","width":1100,"height":618,"caption":"Therapeutics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021341\/business-cocktail-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 19, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 19, 2018 3:38 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2797"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2797\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1914"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2797"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2797"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}